BioAtla, Inc.
BioAtla, Inc. (BCAB) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BCAB · as of Jun 9, 2026
Key Statistics
Explore BioAtla, Inc. Data
bcab stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 9 · Buy rate: 66.7%
The BCAB analyst consensus is Buy, based on ratings from 9 Wall Street analysts over the past 3 months. The average 12-month price target is $250.00, representing +7452.87% upside from the current price of $3.31.
Competitors & Peers
bcab competitorsBCAB
ANVS
BTAI
CELU
EVAX
GBIOStock Performance
Full HistoryAbout BioAtla, Inc.
BioAtla, Inc. BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cance…
what is bioatla, inc. · bcab stock overview · bioatla, inc. company profile · who is bioatla, inc. ceo · bcab NASDAQ · bioatla, inc. headquarters · bioatla, inc. business segments
About Stock Overview & Key Data
BioAtla, Inc. (BCAB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 16, 2020. As of the latest trading session, BCAB stock price is $3.31, with a market capitalization of $4.2M. The stock has returned -86.96% over the past 12 months and -88.34% year-to-date.
According to 9 Wall Street analysts, the consensus rating for BioAtla, Inc. stock is Buy, with an average 12-month price target of $250.00. In fiscal year 2025, BioAtla, Inc. reported revenue of $2.0M and net income of -$59.6M. For detailed data — including BioAtla, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BioAtla, Inc. (BCAB) stock price is $3.31. The stock is traded on NASDAQ under the ticker symbol BCAB. The 52-week range is $3.12 – $71.50.